Efficacy of fasudil for the treatment of aneurysmal subarachnoid hemorrhage

A systematic review protocol of randomized controlled trial

Hao-yan Wang, MMa, Guang-fu Song, MMa, Hong-wei Yang, MBa, Xue-feng Chang, MBb, Ren-bo Shen, MBa, Fu-yi Yang, MBa,*

Abstract

Background: This study aims to systematically assess the efficacy and safety of fasudil for the treatment of aneurysmal subarachnoid hemorrhage (ASH).

Methods: This study will include all of randomized controlled trials on the efficacy and safety of fasudil for the treatment of ASH. Ten electronic databases of PubMed, Embase, Cochrane Library, Google Scholar, Web of Science, Ovid, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure will be searched from inception to the May 1, 2019 without language restrictions. We will also search gray literatures to avoid missing any other potential studies. Two authors will independently perform study selection, data extraction and management, and methodologic quality assessment. The primary outcome is limbs function. The secondary outcomes comprise of muscle strength, muscle tone, quality of life, and adverse events.

Results: This study will provide a comprehensive literature search on the current evidence of fasudil for the treatment of ASH from primary and secondary outcomes.

Conclusion: The results of this study will present evidence to determine whether fasudil is an effective and safety treatment for patients with ASH.

Systematic review registration: PROSPERO CRD42019136215.

Abbreviations:
ASH = aneurysmal subarachnoid hemorrhage, RCTs = randomized controlled trials.

Keywords: aneurysmal subarachnoid hemorrhage, efficacy, fasudil, safety

1. Introduction

Aneurysmal subarachnoid hemorrhage (ASH) is a common and serious disorder that can affect brain with a variety of neurologic conditions.[1,2] It is often associated with high mortality, morbidity, and also heavy healthcare burden.[3,4] It has been reported that ASH accounts for 5% of all strokes; however, its mortality is about 50% (32–67%). Of these, only 30% patients can recover sufficiently to return to independent living.[5–7] It is estimated that the estimated of ASH is about 10.5 per 100,000 persons each year.[8] Its clinical outcomes depend on a variety of factors, such as acute bleed severity, rebleeding, as well as the presence or absence of delayed cerebral ischemia.[9,10]

A variety of managements can help patients with ASH, including statin, clazosentan, cilostazol, simvastatin, diltiazem, simvastatin, methylprednisolone, rehabilitation, and fasudil.[11–23] especially for fasudil. Although several studies have reported that fasudil can be utilized for ASH treatment effectively,[20–23] its conclusion is still unconfirmed. However, no study has systematically assessed the efficacy and safety of fasudil for the treatment of patients with ASH. Therefore, this study will explore the efficacy and safety of fasudil for ASH systematically.

2. Methods and analysis

2.1. Study registration

This study has been registered on PROSPERO (CRD42019136215). This study will follow the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Protocol Statement.

2.2. Inclusion criteria for study selection

2.2.1. Participants/population. Patients diagnosed as having ASH will be included regardless their race, gender, and age.

2.2.2. Interventions/exposure. Studies that assessed the efficacy and safety of fasudil on patients with ASH will be included.

The control interventions will include any other treatments except fasudil.
2.2.3. Study types. We will only consider randomized controlled trials (RCTs) of fasudil for ASH. We will exclude nonclinical studies, non-RCTs, and quasi-RCTs.

2.2.4. Outcome measurements. The primary outcome is limbs function, which can be any relevant scales, such as Fugl Meyer Assessment scale. The secondary outcomes comprise of muscle strength, as measured by motricity index or other related score tools; muscle tone, as assessed by modified Ashworth scale, or other relevant scales; and quality of life, as expressed by activities of daily living scale or any other specific scales. Additionally, we will also assess adverse events.

2.3. Search methods for the identification of studies

Ten electronic databases of PubMed, Embase, Cochrane Library, Google Scholar, Web of Science, Ovid, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure will be searched from inception to the May 1, 2019 for assessing efficacy and safety of fasudil for ASH. The search will be performed without any language restrictions. The fully reproducible search strategy is presented in Table 1 for PubMed. The similar strategy will be adapted to the other electronic databases. Additionally, we will also search gray literatures, such as dissertations, clinical trials registry, and bibliographies.

2.4. Study selection

Two authors will independently scrutinize the literatures involved in fasudil for the treatment of ASH. We will scan the titles and abstracts 1st, and all irrelevant articles will be excluded. Then, full-texts will be read to further determine if those literatures can meet final inclusion criteria. If there are some disagreements occurred between 2 authors, a 3rd author will involve solving those disagreements through discussion. The whole procedure of study selection will be presented in the PRISMA flowchart.

2.5. Data extraction and management

EndNote X7 software will be utilized to manage all the records. All essential data will be extracted from eligible studies by 2 authors independently. A 3rd author will help to solve all the divergences between 2 authors regarding the data extraction. The following information will be extracted according to the previously designed form: title, author, year of publication, journal, location, patient characteristics, inclusion and exclusion criteria, study design, study methods, treatment details, and outcomes.

2.6. Dealing with missing data

If any essential information or data are missing or insufficient, we will contact the primary author to request that information. If we cannot receive it, then we will only analyze available data, and will discuss its potential affects.

2.7. Risk of bias assessment

Two authors will independently assess the risk of bias for each eligible study by using Cochrane Risk of Bias Tool. A 3rd author will involve resolving any disagreements regarding the risk of bias assessment between 2 authors. It comprises of 7 items, and each item will be further judged as 3 aspects: high, unclear, or low risk of bias for each study.

2.8. Reporting bias

When more than 10 eligible RCTs are entered, the Funnel plot and Egger regression test will be adopted to check if there is any reporting bias.

2.9. Statistical analysis

We will use RevMan 5.3 software to perform statistical analysis. We will express all continuous data as mean difference or standardized mean difference with 95% confidence intervals, and all dichotomous data as risk ratio with 95% confidence intervals.

Heterogeneity will be examined by I² test. I² > 50% indicates reasonable heterogeneity, and a fixed-effect model will be used. I² > 50% means significant heterogeneity, and a random-effect model will be applied. At the same time, subgroup analysis will be performed to explore the potential causes of significant heterogeneity. If it is possible, we will conduct data synthesis and meta-analysis. If it is not possible for meta-analysis performance, because of the significant heterogeneity after subgroup analysis, narrative synthesis will be reported.

Subgroup analysis will be conducted according to the different types of treatments, controls, and outcome measurements. In addition, we will also perform sensitivity analysis to check robustness and stability of pooled results by removing studies with high risk bias.

3. Discussion

Previous studies have reported that fasudil can be used to treat ASH effectively. However, its conclusion is still unclear, and no study has systematically addressed the efficacy and safety of
this study will provide present evidence of fasudil for patients with ASH. Therefore, this study will summarize findings of fasudil treatment for patients with ASH. Consequently, this study will provide present evidence of fasudil for patients with ASH. In addition, its results may also provide helpful evidence for both clinical practice and patients.

**Author contributions**

Conceptualization: Hao-yan Wang, Hong-wei Yang, Xue-feng Chang, Ren-bo Shen, Fu-yi Yang.

Data curation: Hao-yan Wang, Guang-fu Song, Fu-yi Yang.

Formal analysis: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Fu-yi Yang.

Funding acquisition: Fu-yi Yang.

Investigation: Hao-yan Wang.

Methodology: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Ren-bo Shen.

Project administration: Fu-yi Yang.

Resources: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Ren-bo Shen.

Software: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Ren-bo Shen.

Supervision: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Ren-bo Shen.

Validation: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Fu-yi Yang.

Visualization: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Ren-bo Shen.

Writing – original draft: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Ren-bo Shen, Fu-yi Yang.

Writing – review & editing: Hao-yan Wang, Guang-fu Song, Hong-wei Yang, Xue-feng Chang, Fu-yi Yang.

**References**

1. Lummel N, Bernau C, Thon N, et al. Prevalence of superficial siderosis following singular, acute aneurysmal subarachnoid hemorrhage. Neuroradiology 2015;57:349–56.

2. Passier PE, Visser-Melby JM, van Zandvoort MJ, et al. Prevalence and determinants of cognitive complaints after aneurysmal subarachnoid hemorrhage. Cerebrovasc Dis 2010;29:557–63.

3. Kao L, Al-Lawati Z, Vavas J, et al. Prevalence and clinical demographics of cerebral salt wasting in patients with aneurysmal subarachnoid hemorrhage. Pituitary 2009;12:347–51.

4. Kundz S, Mahendra V, Gupta V, et al. Principles of neuroanesthesia in aneurysmal subarachnoid hemorrhage. J Anesthesiol Clin Pharmacol 2014;30:328–37.

5. Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol 2014;10:44–58.

6. van Ginj J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007;369:306–8.

7. Passier PE, Visser-Melby JM, Rinkel GJ, et al. Life satisfaction and return to work after aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 2011;20:324–9.

8. de Rooj NK, Linn FH, van der Plas JA, et al. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 2007;78:1361–72.

9. Fujioka T, Yoshimine T. Guidelines for aneurysmal subarachnoid hemorrhage. Nihon Rinsho 2006;16(Suppl 7):289–85.

10. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006;354:387–96.

11. Naraoka M, Matsuda N, Shimamura N, et al. Long-acting statin for aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled trial. J Cereb Blood Flow Metab 2018;38:1150–8.

12. Fujimura M, Joo JY, Kim JS, et al. Preventive effect of cilastatins against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean patients. Cerebrovasc Dis 2017;44:59–67.

13. Matsuda N, Naraoka M, Ohkuma H, et al. Effect of cilastatins on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled trial. Cerebrovasc Dis 2016;42:97–105.

14. Wong GK, Chan DY, Su D, et al. High-dose simvastatin for aneurysmal subarachnoid hemorrhage: multicenter randomized controlled double-blinded clinical trial. Stroke 2015;46:1463–9.

15. Ogura T, Takeda R, Oogawa H, et al. Effects of cilastatin on sympathetic activity in patients with aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 2015;120:47–50.

16. Macdonald RL, Sugihara RT, Keller E, et al. Randomized trial of cilastatin in patients with aneurysmal subarachnoid hemorrhage: multicenter, randomized, controlled, double-blind clinical trial protocol. Neurosurgery 2013;72:640–9.

17. Chen Z, Song W, Du J, et al. Rehabilitation of patients with chronic normal-pressure hydrocephalus after aneurysmal subarachnoid hemorrhage benefits from ventriculo-peritoneal shunt. Top Stroke Rehabil 2009;16:30–8.

18. Gomis P, Graftieaux JP, Sercombe R, et al. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurol 2010;12:681–8.

19. Hanada Y, Kudo H, Kohmura E. Chronicologic changes of fasudil hydrochloride and hydroxyfasudil in cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis 2005;14:47–9.

20. Suzuki Y, Shibuya M, Satoh S, et al. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007;68:1262–71.

21. Zhao J, Zhou D, Guo J, et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2006;46:421–8.

22. Nakashima S, Tabuchi K, Shimokawa S, et al. Combination therapy of fasudil hydrochloride and ozagrel sodium for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 1998;38:805–10.